埃万妥单抗致皮肤不良反应并蜂窝织炎1例  

Dermatologic Adverse Drug Events Associated with Cellulitis Caused by the Use of Amivantamab:A Case Report

作　　者：刘衍盈 颜璐璐 LIU Yanying;YAN Lulu(Department of Dermatology,Affiliated Hospital of Guizhou Medical University,Guiyang 550004,China)

机构地区：[1]贵州医科大学附属医院皮肤科,贵州贵阳550004

出　　处：《中国皮肤性病学杂志》2024年第11期1280-1283,共4页The Chinese Journal of Dermatovenereology

摘　　要：患者男,59岁,头皮、躯干、肢端皮疹伴痒痛1年,加重1个月。1年前患者因“右肺腺癌骨转移”完善基因检测示表皮生长因子(EGFR)第21外显子L858R突变(Ex21.L858R)、间质表皮转化因子(c-MET)基因扩增,接受埃万妥单抗(JNJ-61186372,amivantamab)靶向药物GCPⅢ期临床试验,在每周期用药后2~3 d逐渐出现广泛的痤疮样皮疹、甲沟炎、甲周的渗液和出血,并伴瘙痒、疼痛,皮疹随单抗治疗周期呈反复复发-缓解的趋势,逐渐加重,1个月前接受靶向治疗3 d后上述皮疹加重并出现右下肢红肿热痛。诊断:埃万妥单抗(JNJ-61186372)致皮肤不良反应并蜂窝织炎。患者予苯唑西林钠抗感染、甲泼尼龙琥珀酸钠抗炎及对症治疗后皮损明显消退。A 59-year-old male was enrolled in a phase Ⅲ clinical trial involving amivantamab due to his prior diagnosis of right lung adenocarcinoma with bone metastases one year ago. Genetic testing revealed an L858R point mutation in an epidermal growth factor receptor (EGFR) in exon 21 (Ex21.L858R) and c-mesenchymal epithelial transition factor (c-MET) amplification. Within 2-3 days of starting each treatment cycle with amivantamab, the patient developed widespread acne-like rashes, paronychia, exudation and oozing blood from fingernails and toenails, accompanied by pain and itching. The rash exhibited a recurrent tendency during the treatment cycle and became more severe over time. Three days after starting targeted drug therapy a month ago, the rash worsened and the patient experienced pain, swelling, redness, and burning sensations in the right lower limb. The rash significantly subsided after treatment with benzylpenicillin sodium, methylprednisolone, and symptomatic therapy. The diagnosis confirmed dermatologic adverse drug events associated with cellulitis caused by the use of amivantamab (JNJ-61186372).

关 键 词：埃万妥单抗 皮肤不良反应 蜂窝织炎 

分 类 号：R979.1[医药卫生—药品]